BridgeMD
New treatment option for Liver Fat
Official title Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
ClinicalTrials.gov ID: NCT05644717
What this study is testing
What is Ertugliflozin 5 mg, 15mg?
Ertugliflozin 5 mg, 15mg is an investigational medicine, given as an once-daily, being studied as a potential treatment for liver fat.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Patient able to provide written informed consent
- Adult males \& females between 18 to 65 years
- SGLT2i and insulin naïve patients
- BMI \>23 Kg/m2
- HbA1C % ≥ 6.5 to 10
You likely can't join if
- History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.
- Pioglitazone use in the past 6 months
- History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.
- History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.
- History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)
- History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and/or HIV
See the full eligibility criteria
- Patient able to provide written informed consent
- Adult males \& females between 18 to 65 years
- SGLT2i and insulin naïve patients
- BMI \>23 Kg/m2
- HbA1C % ≥ 6.5 to 10
- Documented hepatic steatosis or fatty liver disease on Ultrasound
- Patient with Type II Diabetes Mellitus
- History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.
- Pioglitazone use in the past 6 months
- History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.
- History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.
- History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)
- History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and/or HIV
- History of recurrent UTIs and mycotic infection.
- Severely ill patients (who have high grade fever, sepsis or acute infection)
- Pregnant woman, lactating woman or planning pregnancy during study duration
- History of Drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines).
- History of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and/or laboratory tests
- Alcohol intake 10 - 30 g/day (three drinks per day) within the previous year
- Active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines.
- Severe hepatic impairment ( AST \& ALT levels \> 3 times upper limit normal
The study team makes the final eligibility decision.
Where it's taking place
- Peshawar, KPK, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Peshawar, KPK, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.